^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

DM919

i
Other names: DM919
Associations
Trials
Company:
D2M biotherap
Drug class:
NK cell stimulant, MICA inhibitor, MICB inhibitor
Related drugs:
Associations
Trials
8ms
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=160, Recruiting, D2M Biotherapeutics Inc. | Active, not recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • DM919
8ms
New P1 trial • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • DM919
2years
DM919, a potent anti-MICA/B antibody, reinforces NKG2D-MICA/B axis and promotes anti-tumor activities in preclinical models (SITC 2022)
Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Preclinical • IO biomarker
|
CD8 (cluster of differentiation 8) • MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
|
DM919